Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2018

29.11.2017 | Laboratory Investigation

Histopathological vascular investigation of the peritumoral brain zone of glioblastomas

verfasst von: Ryota Tamura, Kentaro Ohara, Hikaru Sasaki, Yukina Morimoto, Kazunari Yoshida, Masahiro Toda

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

To date, no histopathological vascular investigation focusing on peritumoral brain zone (PBZ) has been reported for glioblastoma. We analyzed 10 newly diagnosed cases of glioblastomas. For these PBZs, histopathological investigation was performed by hematoxylin–eosin (H&E) staining and immunohistochemistry was analyzed for CD31, CD34, Factor VIII, VEGF, VEGFR-1/2, Ki67, p53 and nestin. Although it was difficult to identify PBZ by H&E, Ki67 and p53 staining, there were apparent differences in nestin staining among PBZ, tumor core (TC), and normal zone (NZ). Therefore, in this study, we divided PBZ from TC and NZ by nestin staining. Differences in histological features, microvessel density, expression of VEGF and its receptors were assessed for PBZ, TC and NZ. The microvessel density, as determined by counting CD31, CD34 and VEGF receptors, and VEGF-A expression were lower in PBZ than TC. The expression patterns for CD31, CD34 and VEGF receptors in vessels show dissociation in PBZ. In addition, the vascular characteristics of the PBZ may correlate with findings of radiographic imaging. We provide the first clinicopathological evidence that PBZ exhibits unique angiogenic characteristics. These in situ observations will help to elucidate the mechanisms of tumor recurrence.
Literatur
1.
Zurück zum Zitat Binder DK, Berger MS (2002) Proteases and the biology of glioma invasion. J Neurooncol 56:149–158CrossRefPubMed Binder DK, Berger MS (2002) Proteases and the biology of glioma invasion. J Neurooncol 56:149–158CrossRefPubMed
2.
Zurück zum Zitat Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474PubMed Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26:2466–2474PubMed
3.
Zurück zum Zitat Zinn P, Majadan B, Sathyan P, Singh S, Majumder S, Jolesz F, Colen R (2011) Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in Glioblastoma multiforme. PLoS ONE 6:e25451CrossRefPubMedPubMedCentral Zinn P, Majadan B, Sathyan P, Singh S, Majumder S, Jolesz F, Colen R (2011) Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in Glioblastoma multiforme. PLoS ONE 6:e25451CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996CrossRefPubMed
5.
Zurück zum Zitat Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefPubMed Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, Reulen HJ (2006) ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol 7:392–401CrossRefPubMed
6.
Zurück zum Zitat Shaw E, Berkey B, Coons S, Bullard D, Brachman D, Buckner J, Stelzer K, Barger G, Brown P, Gilbert M, Mehta M (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835–841CrossRefPubMed Shaw E, Berkey B, Coons S, Bullard D, Brachman D, Buckner J, Stelzer K, Barger G, Brown P, Gilbert M, Mehta M (2008) Recurrence following neurosurgeon-determined gross-total resection of adult supratentorial low-grade glioma: results of a prospective clinical trial. J Neurosurg 109:835–841CrossRefPubMed
7.
Zurück zum Zitat Baumgarten P, Blank A, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach J, Plate K, Harter P, Mittelbronn M (2016) Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 18:173–183CrossRefPubMed Baumgarten P, Blank A, Franz K, Hattingen E, Dunst M, Zeiner P, Hoffmann K, Bähr O, Mäder L, Goeppert B, Machein M, Seifert V, Steinbach J, Plate K, Harter P, Mittelbronn M (2016) Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas. Neuro Oncol 18:173–183CrossRefPubMed
8.
Zurück zum Zitat Folkman J (2007) Angiogenesis: an organizing principle for drug discovery ? Nat Rev Drug Discov 6:273–286CrossRefPubMed Folkman J (2007) Angiogenesis: an organizing principle for drug discovery ? Nat Rev Drug Discov 6:273–286CrossRefPubMed
9.
Zurück zum Zitat Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefPubMed Jain RK, di Tomaso E, Duda DG, Loeffler JS, Sorensen AG, Batchelor TT (2007) Angiogenesis in brain tumours. Nat Rev Neurosci 8:610–622CrossRefPubMed
10.
11.
Zurück zum Zitat Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409–415CrossRefPubMed Chaudhry IH, O’Donovan DG, Brenchley PE, Reid H, Roberts IS (2001) Vascular endothelial growth factor expression correlates with tumour grade and vascularity in gliomas. Histopathology 39:409–415CrossRefPubMed
12.
Zurück zum Zitat Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H (2001) Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir (Wien) 143:159–166CrossRef Yao Y, Kubota T, Sato K, Kitai R, Takeuchi H, Arishima H (2001) Prognostic value of vascular endothelial growth factor and its receptors Flt-1 and Flk-1 in astrocytic tumours. Acta Neurochir (Wien) 143:159–166CrossRef
13.
Zurück zum Zitat Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T, Yoshida K (2013) Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol 72:816–823CrossRefPubMed Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T, Yoshida K (2013) Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis. J Neuropathol Exp Neurol 72:816–823CrossRefPubMed
14.
Zurück zum Zitat Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183CrossRefPubMed Ohgaki H, Kleihues P (2011) Genetic profile of astrocytic and oligodendroglial gliomas. Brain Tumor Pathol 28:177–183CrossRefPubMed
15.
Zurück zum Zitat Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305–316CrossRefPubMedPubMedCentral Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ (2011) Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell 19:305–316CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti (2010) soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115:3843–3851 Harhouri K, Kebir A, Guillet B, Foucault-Bertaud A, Voytenko S, Piercecchi-Marti (2010) soluble CD146 displays angiogenic properties and promotes neovascularization in experimental hind-limb ischemia. Blood 115:3843–3851
17.
Zurück zum Zitat Matsuda Y, Hagio M, Ishiwata T (2013) Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol 19:42–48CrossRefPubMedPubMedCentral Matsuda Y, Hagio M, Ishiwata T (2013) Nestin: a novel angiogenesis marker and possible target for tumor angiogenesis. World J Gastroenterol 19:42–48CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat DeLay M, Jahangiri A, Carbonell W, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aqhi MK (2012) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18:2930–2942CrossRefPubMedPubMedCentral DeLay M, Jahangiri A, Carbonell W, Hu YL, Tsao S, Tom MW, Paquette J, Tokuyasu TA, Aqhi MK (2012) Microarray analysis verifies two distinct phenotypes of glioblastomas resistant to antiangiogenic therapy. Clin Cancer Res 18:2930–2942CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2016) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7:52423–52435PubMedPubMedCentral Tamura R, Tanaka T, Miyake K, Tabei Y, Ohara K, Sampetrean O, Kono M, Mizutani K, Yamamoto Y, Murayama Y, Tamiya T, Yoshida K, Sasaki H (2016) Histopathological investigation of glioblastomas resected under bevacizumab treatment. Oncotarget 7:52423–52435PubMedPubMedCentral
20.
Zurück zum Zitat Jin X, Jin X, Jung JE, Beck S, Kim H (2013) Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 433:496–501CrossRefPubMed Jin X, Jin X, Jung JE, Beck S, Kim H (2013) Cell surface Nestin is a biomarker for glioma stem cells. Biochem Biophys Res Commun 433:496–501CrossRefPubMed
21.
Zurück zum Zitat Ishiwata T, Matsuda Y, Naito Z (2011) Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17:409–418CrossRefPubMedPubMedCentral Ishiwata T, Matsuda Y, Naito Z (2011) Nestin in gastrointestinal and other cancers: effects on cells and tumor angiogenesis. World J Gastroenterol 17:409–418CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Onisim A1, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P (2015) Current insights into the association of Nestin with tumor angiogenesis. J BUON 20:699–706PubMed Onisim A1, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P (2015) Current insights into the association of Nestin with tumor angiogenesis. J BUON 20:699–706PubMed
23.
Zurück zum Zitat Tamagno I, Schiffer D. Nestin expression in reactive astrocytes of human pathology. (2006) J Neurooncol 80:227–233CrossRefPubMed Tamagno I, Schiffer D. Nestin expression in reactive astrocytes of human pathology. (2006) J Neurooncol 80:227–233CrossRefPubMed
24.
Zurück zum Zitat Schmidt NO, Westphal M, Hagel C, Ergün S, Stavrou D, Rosen EM, Lamszus K (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10–18CrossRefPubMed Schmidt NO, Westphal M, Hagel C, Ergün S, Stavrou D, Rosen EM, Lamszus K (1999) Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer 84:10–18CrossRefPubMed
25.
Zurück zum Zitat Uesaka T, Shono T, Suzuki S, Nakamizo A, Niiro H, Mizoguchi M, Iwaki T, Sasaki T (2007) Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83:259–266CrossRefPubMed Uesaka T, Shono T, Suzuki S, Nakamizo A, Niiro H, Mizoguchi M, Iwaki T, Sasaki T (2007) Expression of VEGF and its receptor genes in intracranial schwannomas. J Neurooncol 83:259–266CrossRefPubMed
26.
Zurück zum Zitat Lin C, McGough R, Aswad B, Block JA, Terek R (2004) Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 22:1175–1181CrossRefPubMed Lin C, McGough R, Aswad B, Block JA, Terek R (2004) Hypoxia induces HIF-1alpha and VEGF expression in chondrosarcoma cells and chondrocytes. J Orthop Res 22:1175–1181CrossRefPubMed
27.
Zurück zum Zitat Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967CrossRefPubMed Asahara T, Murohara T, Sullivan A, Silver M, van der Zee R, Li T, Witzenbichler B, Schatteman G, Isner JM (1997) Isolation of putative progenitor endothelial cells for angiogenesis. Science 275:964–967CrossRefPubMed
28.
Zurück zum Zitat Miettinen M, Rikala MS, Rys J, Lasota J, Wang ZF (2012)Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol 36:629–639CrossRefPubMedPubMedCentral Miettinen M, Rikala MS, Rys J, Lasota J, Wang ZF (2012)Vascular endothelial growth factor receptor 2 as a marker for malignant vascular tumors and mesothelioma: an immunohistochemical study of 262 vascular endothelial and 1640 nonvascular tumors. Am J Surg Pathol 36:629–639CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R (2005) Expression of VEGF and its receptors in different brain tumors. Neurol Res 27:371–377CrossRefPubMed Huang H, Held-Feindt J, Buhl R, Mehdorn HM, Mentlein R (2005) Expression of VEGF and its receptors in different brain tumors. Neurol Res 27:371–377CrossRefPubMed
30.
Zurück zum Zitat Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:776–780CrossRefPubMed Hellström M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom P, Alva J, Nilsson AK, Karlsson L, Gaiano N, Yoon K, Rossant J, Iruela-Arispe ML, Kalén M, Gerhardt H, Betsholtz C (2007) Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 445:776–780CrossRefPubMed
31.
Zurück zum Zitat Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196–208CrossRefPubMed Phng LK, Gerhardt H (2009) Angiogenesis: a team effort coordinated by notch. Dev Cell 16:196–208CrossRefPubMed
32.
Zurück zum Zitat Brat DJ, Van Meir EG (2001) Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 158:789–796CrossRefPubMedPubMedCentral Brat DJ, Van Meir EG (2001) Glomeruloid microvascular proliferation orchestrated by VPF/VEGF: a new world of angiogenesis research. Am J Pathol 158:789–796CrossRefPubMedPubMedCentral
33.
Zurück zum Zitat Batchelor T, Duda D, Tomaso E, Ancukiewicz M, Plotkin S, Gerstner E, Eichler A, Drappatz J, Hochberg F, Benner T, Louis D, Cohen K, Chea H, Exarhopoulos A, Loeffler J, Moses M, Ivy P, Sorensen A, Wen P, Jain R (2010) Phase II Study of Cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817–2823CrossRefPubMedPubMedCentral Batchelor T, Duda D, Tomaso E, Ancukiewicz M, Plotkin S, Gerstner E, Eichler A, Drappatz J, Hochberg F, Benner T, Louis D, Cohen K, Chea H, Exarhopoulos A, Loeffler J, Moses M, Ivy P, Sorensen A, Wen P, Jain R (2010) Phase II Study of Cediranib, an oral pan–vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 28:2817–2823CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy CJ, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110:19059–19064CrossRefPubMedPubMedCentral Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy CJ, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF (2013) Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci USA 110:19059–19064CrossRefPubMedPubMedCentral
35.
Zurück zum Zitat Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H (2010) The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem 58:721–730CrossRefPubMedPubMedCentral Suzuki S, Namiki J, Shibata S, Mastuzaki Y, Okano H (2010) The neural stem/progenitor cell marker nestin is expressed in proliferative endothelial cells, but not in mature vasculature. J Histochem Cytochem 58:721–730CrossRefPubMedPubMedCentral
36.
Zurück zum Zitat Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82CrossRefPubMed Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, Frank A, Bayazitov IT, Zakharenko SS, Gajjar A, Davidoff A, Gilbertson RJ (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11:69–82CrossRefPubMed
37.
Zurück zum Zitat Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol 18:1313–1318CrossRefPubMedPubMedCentral Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W (2016) Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol 18:1313–1318CrossRefPubMedPubMedCentral
Metadaten
Titel
Histopathological vascular investigation of the peritumoral brain zone of glioblastomas
verfasst von
Ryota Tamura
Kentaro Ohara
Hikaru Sasaki
Yukina Morimoto
Kazunari Yoshida
Masahiro Toda
Publikationsdatum
29.11.2017
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2018
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-017-2648-9

Weitere Artikel der Ausgabe 2/2018

Journal of Neuro-Oncology 2/2018 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.